US 5,204,356 AGranted

Treatment of anxiety

AssigneeGlaxo Group Limited

InventorMichael B. Tyers

Life of this patent

Estimating the term…

Abstract

The invention relates to the use of compounds which act as 5-hydroxytryptamine (5-HT) antagonists at 5-HT "M" receptors in the treatment of anxiety.

Claims5

Dependent claims

A method for the treatment of anxiety in a human or animal subject suffering from or susceptible to anxiety which comprises administering to the human or animal subject an effective amount for the treatment of anxiety in said subject of an azabicyclo derivative which acts as an antagonist of 5-hydroxytryptamine (5-HT) at 5-HT "M" receptors, wherein said azabicyclo derivative is a conjugate formed from an indole derivative connected by an amide group to a tropyl group;

or a physiologically acceptable salt or solvate thereof.

Dependencies are inferred from the claim text.

Facts

Application: 07/827,511Filed 29 Jan 1992 · continuation
Priority: GB 851865824 Jul 1985
Granted: 20 Apr 1993
Term ends: Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 31/55
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/40
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having five-membered rings with one nitrogen as the only ring hetero atom,…
A61K 31/435
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/445
Non condensed pyridines; Hydrogenated derivatives thereof: non condensed piperidines, e.g. piperocaine

Family

Serial888,467Parent of this continuation · filed 23 Jul 1986
Serial259,719Parent of this division · filed 19 Oct 1988
Serial419,728Parent of this division · filed 11 Oct 1989
Serial530,301Parent of this continuation · filed 30 May 1990
US 4,975,436 AParent of this division
US 4,883,803 AParent of this division
US 5,204,356 AThis patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

The invention relates to the use of compounds which act as 5-hydroxytryptamine (5-HT) antagonists at 5-HT "M" receptors in the treatment of anxiety.

Facts

Application

07/827,511Filed 29 Jan 1992 · continuation

Priority

GB 851865824 Jul 1985

Granted

20 Apr 1993

Term ends

Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 31/55
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/40
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having five-membered rings with one nitrogen as the only ring hetero atom,…
A61K 31/435
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/445
Non condensed pyridines; Hydrogenated derivatives thereof: non condensed piperidines, e.g. piperocaine

Family

Serial888,467Parent of this continuation · filed 23 Jul 1986

Serial259,719Parent of this division · filed 19 Oct 1988

Serial419,728Parent of this division · filed 11 Oct 1989

Serial530,301Parent of this continuation · filed 30 May 1990

US 4,975,436 AParent of this division

US 4,883,803 AParent of this division

US 5,204,356 AThis patent

From the US filing history. Foreign family members aren’t listed.